S. Fukumoto

发表

Effects of 1-year treatment with fluvastatin or pravastatin on bone.

Y. Takeuchi, S. Watanabe, S. Fukumoto, 2001, The American journal of medicine.

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases

M. Wood, S. Takeda, Toshio Matsumoto, 2019, EBioMedicine.

Anti‐FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23

R. Kuroki, T. Shimada, N. Kasai, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The role of bone in phosphate metabolism

S. Fukumoto, 2009, Molecular and Cellular Endocrinology.

Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer

M. Matsuhisa, A. Kuroda, S. Yoshida, 2016, Internal medicine.

The Bone–FGF23–Klotho Axis and Associated Diseases

S. Fukumoto, 2019 .

Enpp1 is an anti-aging factor that regulates Klotho under phosphate overload conditions

Y. Toyama, M. Kuro-o, K. Miyamoto, 2017, Scientific Reports.

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

T. Shigematsu, T. Hosoya, F. Gejyo, 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

Y. Takeuchi, T. Shimada, T. Muto, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Pheochromocytoma with pyrexia and marked inflammatory signs: a paraneoplastic syndrome with possible relation to interleukin-6 production.

E. Ogata, S. Fukumoto, J. Fujisaki, 1991, The Journal of clinical endocrinology and metabolism.

Relationship between actions of transforming growth factor (TGF)‐β and cell surface expression of its receptors in clonal osteoblastic cells

Y. Takeuchi, S. Fukumoto, Y. Takeuchi, 1995, Journal of cellular physiology.

Stimulation of Osteoclast Formation by 1,25-Dihydroxyvitamin D Requires Its Binding to Vitamin D Receptor (VDR) in Osteoblastic Cells: Studies Using VDR Knockout Mice.

S. Takeda, S. Kato, S. Fukumoto, 1999, Endocrinology.

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Y. Takeuchi, T. Fujita, S. Fukumoto, 2002, The Journal of clinical endocrinology and metabolism.

4. Treatment of Secondary Osteoporoses

S. Fukumoto, 2008 .

Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy

Y. Takashi, S. Fukumoto, M. Taguchi, 2017, Endocrine research.

Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder

K. Iseki, N. Fujii, T. Shigematsu, 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

FGF23 beyond Phosphotropic Hormone

Y. Takashi, S. Fukumoto, 2018, Trends in Endocrinology & Metabolism.

Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency.

S. Mu, Y. Yatomi, T. Fujita, 2014, Kidney international.

Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Metabolic Improvement of Poorly Controlled Noninsulin- Dependent Diabetes Mellitus Decreases Bone Turnover*

Y. Totsuka, Toshio Matsumoto, S. Fukumoto, 2022 .

Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients

M. Matsuhisa, K. Miya, Hisato Shima, 2019, Journal of Bone and Mineral Metabolism.

Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia

Yutaka Takahashi, Y. Takeuchi, C. Shin, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23

K. Ozono, Y. Takeuchi, S. Kitanaka, 2021, Journal of Bone and Mineral Metabolism.

Actions and mode of actions of FGF19 subfamily members.

S. Fukumoto, 2008, Endocrine journal.

Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways

Kozo Nakamura, Y. Terauchi, T. Kadowaki, 2006, Journal of cellular biochemistry.

Effect of mechanical unloading and reloading on periosteal bone formation and gene expression in tail-suspended rapidly growing rats.

T. Nakamura, S. Fukumoto, Y. Kodama, 1998, Bone.

Recent advances in the management of osteoporosis

Toshio Matsumoto, S. Fukumoto, 2017, F1000Research.

Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients

Y. Takeuchi, Sumiyo Watanabe, T. Fujita, 2003, Journal of Bone and Mineral Metabolism.

Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.

E. Ogata, Y. Takeuchi, S. Fukumoto, 2000, Biochemical and biophysical research communications.

Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism.

S. Fukumoto, M. Hori, Yuichiro Shimizu, 2011, Endocrinology.

Clinical evaluation of calcium metabolism in adult T-cell leukemia/lymphoma.

K. Yamaguchi, E. Ogata, Toshiki Watanabe, 1988, Archives of internal medicine.

Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.

T. Shimada, T. Fujita, S. Fukumoto, 2010, Kidney international.

Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats.

T. Nakamura, S. Fukumoto, H. Nigi, 1995, Endocrinology.

Dystrobrevin alpha gene is a direct target of the vitamin D receptor in muscle.

S. Takeda, Toshio Matsumoto, Y. Aoki, 2020, Journal of molecular endocrinology.

FGF23-Klotho axis in CKD

Y. Takashi, S. Fukumoto, 2016, Renal Replacement Therapy.

Clinical Aspects of Fibroblast Growth Factor 23

S. Fukumoto, 2013 .

Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation

T. Fujita, S. Fukumoto, M. Taguchi, 2014, Journal of Bone and Mineral Metabolism.

Fibroblast growth factor 23 as a phosphotropic hormone and beyond

S. Fukumoto, Yuichiro Shimizu, 2011, Journal of Bone and Mineral Metabolism.

Natural History of Mineral and Bone Disorders After Living‐Donor Kidney Transplantation: A One‐Year Prospective Observational Study

Y. Shibagaki, T. Fujita, S. Fukumoto, 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.

I. Endo, Hiroyuki Tanaka, Toshio Matsumoto, 2008, Bone.

Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans

S. Takeda, Y. Takeuchi, T. Fujita, 2007, Journal of Bone and Mineral Metabolism.

High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.

M. Nangaku, Y. Takashi, S. Fukumoto, 2016, Endocrine journal.

Transforming growth factor β stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? Molecular and cellular endocrinology, 92 (1993) 55–62

J. A. Glatz, T. Martin, M. Gillespie, 1993, Molecular and Cellular Endocrinology.

Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine

E. Itoi, H. Ozawa, S. Kokubun, 2015, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

Osteomalacia Caused by Skull Base Tumors: Report of 2 Cases

K. Kawai, N. Saito, J. Shibahara, 2011, Neurosurgery.

Ghrelin Directly Regulates Bone Formation

S. Takeda, K. Kangawa, H. Ishikawa, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor‐Induced Osteomalacia: Outcome of a Retrospective Surveillance

M. Nangaku, K. Ohnaka, Y. Takeuchi, 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Klotho—the discovery of the FGF23 coreceptor

S. Fukumoto, 2021 .

Fibroblast growth factor receptor as a potential candidate for phosphate sensing.

Y. Takashi, S. Fukumoto, 2020, Current opinion in nephrology and hypertension.

Phosphate-sensing and regulatory mechanism of FGF23 production

Y. Takashi, S. Fukumoto, 2020, Journal of Endocrinological Investigation.

Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23

S. Fukumoto, N. Ito, 2020, Calcified Tissue International.

Fibroblast growth factor 23

S. Fukumoto, 2020, Principles of Bone Biology.

Phosphate Metabolism, Hyperphosphatemia, and Hypophosphatemia

S. Fukumoto, 2019, Encyclopedia of Endocrine Diseases.

Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO)

H. Mano, M. Nangaku, M. Fukayama, 2018, Bone reports.

FGF23 and Bone and Mineral Metabolism.

S. Fukumoto, 2019, Handbook of experimental pharmacology.

FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism

S. Fukumoto, 2015, Calcified Tissue International.

What can FGF23 do without Klotho?

S. Fukumoto, 2014, BoneKEy reports.

Phosphate metabolism and vitamin D.

S. Fukumoto, 2014, BoneKEy reports.

Anti-fibroblast growth factor 23 antibody therapy

S. Fukumoto, 2014, Current opinion in nephrology and hypertension.

FGF23 as a novel therapeutic target.

T. Shimada, S. Fukumoto, 2012, Advances in experimental medicine and biology.

Phosphate metabolism: Meeting report from the 32nd annual meeting of the American Society for bone and mineral research October 15-19, 2010 in Toronto, Ontario, Canada

S. Fukumoto, 2010 .

FGF23: Phosphate metabolism and beyond

S. Fukumoto, 2010 .

FGF 23 as a Pathological Humoral Factor in Hypophosphatemic Diseases

S. Fukumoto, 2010 .

Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism

S. Fukumoto, Tasuku Saito, 2009, International journal of pediatric endocrinology.

Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23.

S. Fukumoto, 2008, Internal medicine.

FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

S. Fukumoto, T. Yamashita, 2007, Bone.

Persistent Activation of Calcium‐Sensing Receptor Suppresses Bone Turnover, Increases Microcracks, and Decreases Bone Strength

Kiyoe Kurahashi, I. Endo, Toshio Matsumoto, 2019, JBMR plus.

Parathyroid Hormone‐Related Protein Induced Coupled Increases in Bone Formation and Resorption Markers for 7 Years in a Patient With Malignant Islet Cell Tumors

Y. Takeuchi, T. Fujita, S. Fukumoto, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production.

E. Ogata, Y. Ueyama, N. Tamaoki, 1989, Endocrinology.

Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells

S. Fukumoto, M. Taguchi, Y. Kinoshita, 2016, Journal of Bone and Mineral Metabolism.

Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.

Yoshiya Tanaka, S. Fukumoto, Y. Okada, 2012, Internal medicine.

Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.

T. Fujita, T. Sugimoto, S. Fukumoto, 2009, Bone.

Intravenous Calcitriol Therapy Increases Serum Concentrations of Fibroblast Growth Factor-23 in Dialysis Patients with Secondary Hyperparathyroidism

S. Fukumoto, M. Fukagawa, H. Nishi, 2005, Nephron Clinical Practice.

Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

T. Yoneya, Y. Takeuchi, K. Okawa, 2002, Endocrinology.

Post‐translational Modification of Fibroblast Growth Factor 23

S. Fukumoto, 2005, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Incidence rate and characteristics of symptomatic vitamin D deficiency in children: a nationwide survey in Japan.

H. Tsukahara, K. Ihara, K. Ozono, 2018, Endocrine journal.

Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

T. Shimada, T. Fujita, S. Fukumoto, 2005, American journal of physiology. Renal physiology.

Vitamin D receptor-independent FGF 23 actions in regulating phosphate and vitamin D metabolism

T. Shimada, T. Fujita, S. Fukumoto, 2005 .

Targeted ablation of Fgf 23 demonstrates an essential physiological role of FGF 23 in phosphate and vitamin D metabolism

Y. Takeuchi, T. Shimada, T. Fujita, 2004 .

Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature

S. Fukumoto, E. Hsieh, X. Xing, 2019, Calcified Tissue International.

Mutational analysis of patients with FGF23-related hypophosphatemic rickets.

T. Fujita, S. Fukumoto, T. Igarashi, 2012, European journal of endocrinology.

A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene.

S. Fukumoto, T. Igarashi, Tasuku Saito, 2011, Bone.

Familial hypophosphatemic rickets caused by a large deletion in PHEX gene.

T. Fujita, S. Fukumoto, Hisanori Suzuki, 2009, European journal of endocrinology.

Reduced Expression of Interleukin‐11 in Bone Marrow Stromal Cells of Senescence‐Accelerated Mice (SAMP6): Relationship to Osteopenia with Enhanced Adipogenesis

Toshio Matsumoto, Y. Takeuchi, T. Fujita, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Association between activating mutations of calcium-sensing receptor and Bartter's syndrome

Y. Takeuchi, Sumiyo Watanabe, T. Fujita, 2002, The Lancet.

Inactivating Mutations of Calcium-Sensing Receptor Results in Parathyroid Lipohyperplasia

Y. Takeuchi, T. Fujita, S. Fukumoto, 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

S. Fukumoto, T. Yamashita, 2003, The New England journal of medicine.

Central control of bone remodeling by neuromedin U

Takahiro Matsumoto, S. Takeda, S. Kato, 2007, Nature Medicine.

How do we sense phosphate to regulate serum phosphate level?

Y. Takashi, Toshio Matsumoto, S. Fukumoto, 2019, Journal of Bone and Mineral Metabolism.

FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

T. Yoneya, Y. Takeuchi, T. Shimada, 2004, Biochemical and biophysical research communications.

Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin

S. Fukumoto, T. Yamashita, 2002, Current opinion in nephrology and hypertension.

Cloning and Characterization of Two Promoters for the Human Calcium-sensing Receptor (CaSR) and Changes of CaSR Expression in Parathyroid Adenomas*

Toshio Matsumoto, T. Fujita, S. Fukumoto, 2000, The Journal of Biological Chemistry.

Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia.

Sumiyo Watanabe, S. Fukumoto, M. Taguchi, 2014, The Journal of clinical endocrinology and metabolism.

FGF23 and Hypophosphatemic Rickets/Osteomalacia

Y. Takashi, S. Fukumoto, Daiji Kawanami, 2021, Current Osteoporosis Reports.

S. Fukumoto, 2020, Journal of molecular endocrinology.

Approach to patients with hypophosphataemia.

M. Collins, S. Fukumoto, S. Minisola, 2020, The lancet. Diabetes & endocrinology.

Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia

S. Fukumoto, 2014, Endocrinology and metabolism.

What's new in FGF23 research?

S. Fukumoto, 2012, BoneKEy reports.

[Case report; A case of FGF23-related hypophosphatemic osteomalacia caused by long-term administration of saccharated ferric oxide].

T. Fujita, S. Fukumoto, M. Taguchi, 2011, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.

I. Endo, Toshio Matsumoto, K. Ozono, 2015, Endocrine journal.

Therapeutic Effects of Anti‐FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia

T. Shimada, T. Fujita, S. Fukumoto, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Hyperostosis–Hyperphosphatemia Syndrome: A Congenital Disorder of O‐Glycosylation Associated With Augmented Processing of Fibroblast Growth Factor 23

Y. Frishberg, T. Fujita, S. Fukumoto, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors

Y. Takashi, S. Fukumoto, S. Tajima, 2016, Medical Molecular Morphology.

A ESRD patient with FJHN due to UMOD gene mutation evaluated by ultrasonography

S. Fukumoto, S. Uchida, S. Oba, 2009 .

Pathogenesis and diagnostic criteria for rickets and osteomalacia—proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society

Toshio Matsumoto, K. Ozono, Y. Takeuchi, 2015, Journal of Bone and Mineral Metabolism.

GH Inhibits Interferon-γ-Induced Signal Transducer and Activator of Transcription-1 Activation and Expression of the Inducible Isoform of Nitric Oxide Synthase in INS-1 Cells.

N. Sekine, T. Fujita, S. Fukumoto, 2001, Endocrinology.

Changes in bone metabolic parameters following oral calcium supplementation in an adult patient with vitamin D-dependent rickets type 2A.

M. Nangaku, S. Fukumoto, N. Makita, 2017, Endocrine journal.

Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?

S. Fukumoto, 2018, Front. Endocrinol..

Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia.

S. Fukumoto, M. Taguchi, Y. Kinoshita, 2014, Bone.

Comparison of two assays for fibroblast growth factor (FGF)-23

Y. Takeuchi, T. Fujita, S. Fukumoto, 2005, Journal of Bone and Mineral Metabolism.

Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.

Kozo Nakamura, Sayoko Ogura, Y. Takeuchi, 2004, The Journal of clinical endocrinology and metabolism.

Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia.

S. Fukumoto, T. Yamashita, 2001, Endocrine journal.

Decreased AP‐1 Activity and Interleukin‐11 Expression by Bone Marrow Stromal Cells May Be Associated With Impaired Bone Formation in Aged Mice

Toshio Matsumoto, N. Yamamoto, Y. Takeuchi, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases

M. Zillikens, J. Body, S. Fukumoto, 2022, Calcified Tissue International.

Tumor-induced Osteomalacia Caused by a Parotid Tumor

M. Nangaku, Y. Takashi, N. Egami, 2017, Internal medicine.

Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism.

T. Shigematsu, T. Shimada, S. Fukumoto, 2004, European journal of endocrinology.

Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23.

K. Nanjo, M. Nishi, H. Furuta, 2008, Internal medicine.

Plasminogen activator regulation in osteoblasts: Parathyroid hormone inhibition of type‐1 plasminogen activator inhibitor and its mRNA

T. Gelehrter, S. Fukumoto, E. Allan, 1992, Journal of cellular physiology.

Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation.

T. Shigematsu, S. Fukumoto, M. Fukagawa, 2005, The Journal of clinical endocrinology and metabolism.

Fibroblast growth factor (FGF)23 in patients with acromegaly.

S. Yamada, Y. Takeuchi, T. Fujita, 2007, Endocrine journal.

Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice.

S. Takeda, S. Kato, K. Sekine, 1999, Endocrinology.

Rapid Recovery of Hypothalamic-Pituitary Axis after Successful Resection of an ACTH-secreting Neuroendocrine Tumor.

Katsutoshi Takahashi, M. Nangaku, Y. Takashi, 2015, Internal medicine.

[Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia].

S. Fukumoto, Y. Kinoshita, 2014, Clinical calcium.

Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation.

T. Shigematsu, S. Fukumoto, M. Fukagawa, 2007, Endocrine journal.

Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption

M. Nangaku, M. Katsura, S. Fukumoto, 2021, Bone reports.

Pathogenesis and diagnostic criteria for rickets and osteomalacia - proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society.

Toshio Matsumoto, K. Ozono, Y. Takeuchi, 2015, Endocrine journal.

Evaluation of a new automated chemiluminescence immunoassay for FGF23

T. Fujita, S. Fukumoto, Yuichiro Shimizu, 2012, Journal of Bone and Mineral Metabolism.

Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour‐induced osteomalacia

M. Akahane, T. Fujita, T. Saito, 2010, Journal of internal medicine.

Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.

T. Takato, T. Ogasawara, S. Fukumoto, 2010, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

Runx1 and Runx2 cooperate during sternal morphogenesis

S. Takeda, S. Iseki, T. Imamura, 2010, Development.

Blood Ca2+ modulates responsiveness of renal 25(OH)D3-1 alpha-hydroxylase to PTH in rats.

E. Ogata, S. Fukumoto, K. Ikeda, 1987, The American journal of physiology.

No enzyme activity of 25-hydroxyvitamin D3 1alpha-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation.

S. Kato, A. Murayama, K. Inouye, 1999, The Journal of clinical endocrinology and metabolism.

Transcriptional Regulation of 25-Hydroxyvitamin D-24-Hydroxylase (CYP24A1) by Calcemic Factors in Keratinocytes.

S. Fukumoto, T. Kurokawa, S. Sawatsubashi, 2021, Journal of nutritional science and vitaminology.

A family of autosomal dominant hypocalcemia with an activating mutation of calcium-sensing receptor gene.

Y. Takeuchi, Sumiyo Watanabe, T. Fujita, 2003, Endocrine journal.

Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro.

T. Tsuruo, N. Fujita, Y. Takeuchi, 2002, Endocrine journal.

Focal Adhesion Kinase Activity Is Required for Bone Morphogenetic Protein—Smad1 Signaling and Osteoblastic Differentiation in Murine MC3T3‐E1 Cells

K. Miyazono, Y. Takeuchi, S. Fukumoto, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

GH inhibits interferon-gamma-induced signal transducer and activator of transcription-1 activation and expression of the inducible isoform of nitric oxide synthase in INS-1 cells.

N. Sekine, S. Fukumoto, T. Okazaki, 2001, Endocrinology.

Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] metabolism in vitamin D-deficient rats infused with 1,25-(OH)2D3.

E. Ogata, S. Fukumoto, K. Ikeda, 1989, Endocrinology.

Renal magnesium wasting in a patient with short bowel syndrome with magnesium deficiency: effect of 1 alpha-hydroxyvitamin D3 treatment.

E. Ogata, S. Fukumoto, T. Matsumoto, 1987, The Journal of clinical endocrinology and metabolism.

A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy

E. Ogata, Y. Ueyama, N. Tamaoki, 1988, Calcified Tissue International.

Oncogenic osteomalacia caused by an occult paranasal sinus tumor.

Katsumasa Takahashi, S. Fukumoto, J. Hirato, 2015, Auris, nasus, larynx.

Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review

M. Matsuhisa, A. Kuroda, S. Yoshida, 2017, Internal medicine.

Glucocorticoid regulation of plasminogen activator inhibitor-1 messenger ribonucleic acid and protein in normal and malignant rat osteoblasts.

T. Martin, T. Gelehrter, S. Fukumoto, 1992, Endocrinology.

Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia

Sakae Tanaka, S. Fukumoto, T. Akiyama, 2017, International Orthopaedics.

Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23.

N. Saito, M. Ikemura, S. Fukumoto, 2017, Endocrine journal.

Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation

M. Matsuhisa, M. Nangaku, S. Kato, 2019, Proceedings of the National Academy of Sciences.

The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study.

Y. Shibagaki, T. Fujita, S. Fukumoto, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Secretion of parathyroid hormone-like activity from human T-cell lymphotropic virus type I-infected lymphocytes.

E. Ogata, Toshiki Watanabe, S. Fukumoto, 1989, Cancer research.

Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review

S. Cremers, P. Houillier, D. Shoback, 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Assay of serum pyridinoline: a potential marker for bone resorption.

S. Fukumoto, T. Matsumoto, K. Hata, 1995, Clinica chimica acta; international journal of clinical chemistry.

Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.

E. Ogata, H. Nawata, S. Fukumoto, 1994, The Journal of clinical endocrinology and metabolism.

Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome.

F. Glorieux, K. Ozono, Y. Imanishi, 2014, Bone.

A New Synthetic Steroid, Osaterone Acetate (TZP‐4238), Increases Cortical Bone Mass and Strength by Enhancing Bone Formation in Ovariectomized Rats

E. Ogata, H. Sone, S. Fukumoto, 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia.

Y. Totsuka, Y. Takeuchi, T. Fujita, 1999, The Journal of clinical endocrinology and metabolism.

A family of autosomal dominant hypocalcemia with a positive correlation between serum calcium and magnesium: identification of a novel gain of function mutation (Ser(820)Phe) in the calcium-sensing receptor.

N. Nagata, S. Fukumoto, H. Yasuda, 2002, The Journal of clinical endocrinology and metabolism.

Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23

S. Fukumoto, N. Ito, 2020, Calcified Tissue International.

FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism

S. Fukumoto, 2016, Calcified Tissue International.

Inhibition of Bone Resorption by Pamidronate Cannot Restore Normal Gain in Cortical Bone Mass and Strength in Tail‐Suspended Rapidly Growing Rats

H. Kawahara, Toshitaka Nakamura, Toshio Matsumoto, 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Calcilytic Ameliorates Abnormalities of Mutant Calcium‐Sensing Receptor (CaSR) Knock‐In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH)

H. Kiyonari, I. Endo, Toshio Matsumoto, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Klotho converts canonical FGF receptor into a specific receptor for FGF23

K. Okawa, T. Shimada, T. Fujita, 2006, Nature.

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

S. Takeda, S. Mizutani, T. Yoneya, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Receptor Tyrosine Kinases Inhibit Bone Morphogenetic Protein‐Smad Responsive Promoter Activity and Differentiation of Murine MC3T3‐E1 Osteoblast‐like Cells

K. Miyazono, G. Rodan, Y. Takeuchi, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A microRNA regulatory mechanism of osteoblast differentiation

S. Takeda, H. Ochi, Shingo Sato, 2009, Proceedings of the National Academy of Sciences.

Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in Mice*

S. Takeda, G. Ishii, Toshio Matsumoto, 2002, The Journal of Biological Chemistry.

Stimulation of Smad1 Transcriptional Activity by Ras‐Extracellular Signal‐Regulated Kinase Pathway: A Possible Mechanism for Collagen‐Dependent Osteoblastic Differentiation

K. Miyazono, S. Kato, Y. Takeuchi, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro1.

Y. Takeuchi, M. Miyamoto, T. Fujita, 1999, Endocrinology.

Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro.

K. Miyazono, N. Ueno, S. Kato, 1999, Endocrinology.

Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro *

Y. Takeuchi, M. Miyamoto, S. Fukumoto, 1999 .

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Y. Takeuchi, T. Shimada, T. Fujita, 2004, The Journal of clinical investigation.

Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase‐type PA, PA inhibitor‐1 mRNA, and protein in rat osteoblast‐like cells

T. Gelehrter, S. Fukumoto, R. Zeheb, 1991, Journal of cellular physiology.

The distinct role of the Runx proteins in chondrocyte differentiation and intervertebral disc degeneration: findings in murine models and in human disease.

H. Haro, S. Takeda, M. Osaki, 2008, Arthritis and rheumatism.

Vitamin K(2) inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures.

Y. Takeuchi, S. Fukumoto, T. Fujita, 2000, Bone.

Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.

S. Fukumoto, M. Miura, R. Okazaki, 1999, Endocrine journal.

Single-cell RNA sequencing identifies Fgf23-expressing osteocytes in response to 1,25-dihydroxyvitamin D3 treatment

A. Kawabata, Ayako Hanai, S. Fukumoto, 2023, Frontiers in Physiology.

The Difficult Diagnosis of Hypophosphatemic Rickets-A Review of 8 Clinical Cases

R. Ivanova, S. Fukumoto, A. Borissova, 2020 .

X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.

S. Fukumoto, Y. Kinoshita, 2018, Endocrine reviews.

Bone as an endocrine organ

T. Martin, S. Fukumoto, T. Martin, 2009, Trends in Endocrinology & Metabolism.

A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.

Y. Takeuchi, J. Silver, T. Fujita, 2005, The Journal of clinical endocrinology and metabolism.

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

T. Shigematsu, F. Gejyo, S. Fukumoto, 2005, Kidney international.

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

I. Narita, F. Gejyo, S. Fukumoto, 2005, Kidney international.

Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator?

Jane M. Moseley, J. A. Glatz, T. Martin, 1993, Molecular and Cellular Endocrinology.

Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts.

T. Martin, S. Fukumoto, E. Allan, 1994, Biochimica et biophysica acta.

Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib.

E. Ogata, Y. Takeuchi, S. Fukumoto, 1996, The Journal of clinical endocrinology and metabolism.

Long-term clinical course of IgG4-related systemic disease accompanied by hypophysitis.

T. Fujita, S. Fukumoto, H. Takiyama, 2010, Endocrine journal.

[Symptoms and management of tetany].

S. Fukumoto, N. Ito, 2007, Clinical calcium.

Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.

K. Vandyke, S. Fitter, C. Schultz, 2013, The Journal of clinical endocrinology and metabolism.

Causes and differential diagnosis of hypocalcemia--recommendation proposed by expert panel supported by ministry of health, labour and welfare, Japan.

I. Endo, Hiroyuki Tanaka, Toshio Matsumoto, 2008, Endocrine journal.

An adult patient with severe hypercalcaemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium‐sensing receptor

S. Takeda, Toshio Matsumoto, Y. Takeuchi, 1999, Clinical endocrinology.

Expression of parathyroid hormone-related protein in a human T cell lymphotrophic virus type I-infected T cell line.

T. Watanabe, E. Ogata, T. Motokura, 1988, Biochemical and biophysical research communications.

Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors

M. Nangaku, Y. Takashi, M. Katsura, 2022, Journal of the Endocrine Society.

Tumour-induced osteomalacia

M. Collins, M. Peacock, S. Fukumoto, 2017, Nature Reviews Disease Primers.

Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia.

Y. Takeuchi, S. Fukumoto, T. Fujita, 1999, Bone.

Bone Impairment in a Large Cohort of Chinese Patients With Tumor‐Induced Osteomalacia Assessed by HR‐pQCT and TBS

W. Lv, S. Fukumoto, X. Xing, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23.

T. Suda, S. Fukumoto, N. Yagihashi, 2008, Internal medicine.

Faculty Opinions recommendation of The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study.

Toshio Matsumoto, S. Fukumoto, 2016 .

Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR

T. Yoneda, T. Taguchi, S. Horie, 2020, Journal of Bone and Mineral Metabolism.

An instructive case suggesting cyclical primary hyperparathyroidism.

T. Fujita, S. Fukumoto, T. Okazaki, 2006, Endocrine journal.

Heterozygous gsp mutation renders ion channels of human somatotroph adenoma cells unresponsive to growth hormone-releasing hormone.

K. Takakura, T. Fujita, S. Fukumoto, 1999, Endocrinology.

Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia.

S. Takeda, Y. Takeuchi, S. Fukumoto, 1996, The Journal of clinical endocrinology and metabolism.

Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma.

E. Ogata, T. Motokura, S. Fukumoto, 1989, Annals of internal medicine.

Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study

H. Cheong, K. Ozono, S. Fukumoto, 2020, BMJ Open.

Parathyroid hormone increases the expression level of matrix metalloproteinase-13 in vivo

S. Fukumoto, N. Endo, K. Tokunaga, 2001, Journal of Bone and Mineral Metabolism.

Three-dimensional fluoroscopic navigation-assisted surgery for tumors in patients with tumor-induced osteomalacia in the bones

Sakae Tanaka, H. Oka, S. Fukumoto, 2017, Computer assisted surgery.

[Case report ; a case of Bardet-Biedl syndrome with a pituitary tumor and growth hormone deficiency].

Kumiko Tanaka, K. Takano, T. Fujita, 2013, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia

Y. Shibagaki, T. Fujita, S. Fukumoto, 2007, Clinical and Experimental Nephrology.

Osteoblast/osteocyte-derived interleukin-11 regulates osteogenesis and systemic adipogenesis

H. Kiyonari, S. Kato, T. Nakashima, 2021, Nature Communications.

Recent basic and clinical findings concerning FGF23, a bone-derived hormone

S. Fukumoto, 2023, Current Opinion in Endocrine and Metabolic Research.

Anti‐FGF‐23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice

T. Shimada, T. Fujita, S. Fukumoto, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

TUMOR-INDUCED OSTEOMALACIA: A COMPREHENSIVE REVIEW.

R. Thakker, A. Scillitani, S. Fukumoto, 2022, Endocrine reviews.

Association of primary hyperparathyroidism with myotonic dystrophy in two patients.

E. Ogata, Y. Ihara, S. Fukumoto, 1987, Archives of internal medicine.

Incidence of complications in 25 adult patients with X-linked hypophosphatemia.

M. Nangaku, Y. Taniguchi, S. Fukumoto, 2021, The Journal of clinical endocrinology and metabolism.

Epidermal growth factor-stimulated parathyroid hormone-related protein expression involves increased gene transcription and mRNA stability.

J. Heath, T. Martin, M. Gillespie, 1995, The Biochemical journal.

Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span

M. Matsuhisa, Y. Takashi, I. Endo, 2021, Biochemistry and biophysics reports.

Effect of conventional treatment on dental complications and ectopic ossifications among 30 adults with XLH.

M. Nangaku, T. Ogasawara, Y. Taniguchi, 2022, The Journal of clinical endocrinology and metabolism.

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report

Y. Takashi, H. Yokomizo, S. Fukumoto, 2022, Frontiers in Endocrinology.

Development of versatile non-homologous end joining-based knock-in module for genome editing

Toshio Matsumoto, S. Fukumoto, S. Sawatsubashi, 2018, Scientific Reports.

1. Regulation of Phosphorus-Vitamin D Metabolism by Fibroblast Growth Factor (FGF) 23

S. Fukumoto, 2007 .

[Fibroblast growth factor (FGF)-23 in patients with hypoparathyroidism].

T. Shigematsu, S. Fukumoto, M. Fukagawa, 2005, Clinical calcium.

[Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].

S. Fukumoto, 2007, Rinsho byori. The Japanese journal of clinical pathology.

Some aspects of the anabolic action of parathyroid hormone.

T. Martin, S. Fukumoto, J. Moseley, 1995, Mineral and Electrolyte Metabolism.

The plasminogen activator and inhibitor system in bone remodelling.

T. Martin, S. Fukumoto, E. Allan, 1993, Growth regulation.

Prevalence of pseudohypoparathyroidism and nonsurgical hypoparathyroidism in Japan in 2017: A nationwide survey.

K. Ozono, S. Fukumoto, Yosikazu Nakamura, 2022, Journal of Epidemiology.

[Transport of minerals in renal tubules and its hormonal regulation].

S. Fukumoto, 2007, Clinical calcium.

A novel mutation in the GATA3 gene of a Japanese patient with PTH-deficient hypoparathyroidism

T. Fujita, S. Fukumoto, Hisanori Suzuki, 2008, Journal of Bone and Mineral Metabolism.

Marked hypercalcemia in a patient with hypocalciuric hypercalcemia without a mutation in the calcium-sensing receptor gene.

M. Menju, T. Maruyama, I. Konishi, 2002, Internal medicine.

Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO)

H. Mano, M. Nangaku, M. Fukayama, 2018, Bone reports.

Anti-fibroblast growth factor 23 antibody therapy

S. Fukumoto, 2014, Current opinion in nephrology and hypertension.

Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study

Y. Takeuchi, Y. Imanishi, S. Fukumoto, 2020, Journal of Bone and Mineral Metabolism.

[Disorders of phosphate metabolism].

S. Fukumoto, 2010, Rinsho byori. The Japanese journal of clinical pathology.

Calcilytic Ameliorates Abnormalities of Mutant Calcium‐Sensing Receptor (CaSR) Knock‐In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH)

H. Kiyonari, I. Endo, Toshio Matsumoto, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism caused by inactivating mutations of calcium-sensing receptor].

Sumiyo Watanabe, S. Fukumoto, 2002, Nihon rinsho. Japanese journal of clinical medicine.